Halozyme Therapeutics (HALO) Change in Receivables (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Change in Receivables of $19.5 million for Q1 2026, up 609.83% year-over-year from $2.8 million in Q1 2025, and down 78.4% quarter-over-quarter from $90.5 million in Q4 2025.
Halozyme Therapeutics (HALO) Change in Receivables (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Change in Receivables for 17 consecutive years, with $19.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 609.83% year-over-year to $19.5 million; the TTM figure through Mar 2026 stood at $151.4 million (up 39.3% YoY), while the FY2025 annual figure was $128.1 million, up 72.49% from the prior year.
- Change in Receivables slipped to $19.5 million in Q1 2026 per HALO's latest filing, from $90.5 million in the prior quarter.
- Across five years, Change in Receivables topped out at $90.5 million in Q4 2025 and bottomed at -$38.3 million in Q1 2024.
- Historically, Change in Receivables has averaged $18.2 million across 5 years, with a median of $18.6 million in 2024.
- Annual changes were most pronounced in 2023 — Change in Receivables plunged 258.81% — and 2026, when it surged 609.83%.
- Halozyme Therapeutics' Change in Receivables stood at $7.8 million in 2022, then soared by 117.73% to $16.9 million in 2023, then soared by 34.51% to $22.7 million in 2024, then surged by 298.39% to $90.5 million in 2025, then slumped by 78.4% to $19.5 million in 2026.
- Business Quant data shows HALO's Change in Receivables at $19.5 million in Q1 2026, $90.5 million in Q4 2025, and $29.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | -2.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.16 Mn |
| Jun 30, 2026 | -2.16 Mn |
| Mar 31, 2026 | 19.55 Mn |
| Mar 31, 2026 | 19.55 Mn |
| Dec 31, 2025 | 90.48 Mn |
| Dec 31, 2025 | 90.48 Mn |
| Sep 30, 2025 | 29.70 Mn |
| Sep 30, 2025 | 29.70 Mn |
| Jun 30, 2025 | 11.72 Mn |
| Jun 30, 2025 | 11.72 Mn |
| Mar 31, 2025 | -3.83 Mn |
| Mar 31, 2025 | -3.83 Mn |
| Dec 31, 2024 | 22.71 Mn |
| Dec 31, 2024 | 22.71 Mn |
| Sep 30, 2024 | 71.22 Mn |
| Sep 30, 2024 | 71.22 Mn |
| Jun 30, 2024 | 18.62 Mn |
| Jun 30, 2024 | 18.62 Mn |
| Mar 31, 2024 | -38.31 Mn |
| Mar 31, 2024 | -38.31 Mn |